1. Morgan SG, Bathula HS, Moon S. Pricing of pharmaceuticals is becoming a major challenge for health systems. BMJ. 2020;13:368.
2. Auraaen A, Fujisawa R, Lagasnerie G de, Paris V. How OECD health systems define the range of good and services to be financed collectively [Internet]. Paris: OECD; 2016 [cited 2023 Apr 4]. https://www.oecd-ilibrary.org/social-issues-migration-health/how-oecd-health-systems-define-the-range-of-good-and-services-to-be-financed-collectively_5jlnb59ll80x-en.
3. Panteli D, Arickx F, Cleemput I, Dedet G, Eckhardt H, Fogarty E, et al. Pharmaceutical regulation in 15 European countries. Health Syst Transit. 2016;18(5):1–118.
4. Haute Autorité de Santé. Service médical rendu (SMR) Le médicament a-t-il suffisamment d’intérêt clinique pour être pris en charge par la solidarité nationale ? 2017.
5. Australian Government. Department of Health. Pharmaceutical Benefits Scheme (PBS) | Pharmaceutical Benefits Advisory Committee (PBAC) Membership [Internet]. 2021 [cited 2021 Oct 19]. https://www.pbs.gov.au/info/industry/listing/participants/pbac.